Charged Alpha logo
CHARGED ALPHA
Stock Analysis
Stock Library / TECH
TECH Healthcare Latest YouTube: Q3 FY2026 Published 2026-05-07

Bio-Techne Corporation

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest earnings video

TECH Stock: Revenue Misses by 1% — Q3 FY2026

Published 2026-05-07

Library coverage

Episodes tracked
1
Episodes linked
1
Latest video
Q3 FY2026
2026-05-07
Podcast available
Yes
Current price
$72.32
+0.04 (+0.06%)
Trailing / Forward P/E
62.34x
Forward: 31.21x
Market cap / Volume
Volume:
Revenue / Earnings Growth
1.3%
Earnings: —
Margins
23.5% op
Gross: 66.2% · Net: 15.0%
Balance sheet
4.55x current
Debt / Equity: 13.7
52-week range / Beta
$43.20 - $72.62
Beta: 1.28
Analyst target
$70.73
Upside: -2.2%
Cash / shareholder return
1.99% FCF yield
Dividend yield: 0.44%

Company context

Industry: Biotechnology
Country: United States
Employees:
Price to book: 5.43x
Return on equity: 9.0%
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Price chart

Market context for TECH

Competitive view

TECH vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

Bio-Techne Corporation latest YouTube video thumbnail YouTube
Bio-Techne Corporation
TECH
Latest video
Q3 FY2026
Growth profile looks mature or currently muted, which can cap multiple expansion unless execution improves.
Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.
Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Intuitive Surgical latest YouTube video thumbnail YouTube
Intuitive Surgical
ISRG
Latest video
Q2 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Johnson & Johnson latest YouTube video thumbnail YouTube
Johnson & Johnson
JNJ
Latest video
Q2 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.
Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
TECH
$11.27B
Bio-Techne Corporation
ISRG
$135.72B
Intuitive Surgical
JNJ
$651.25B
Johnson & Johnson
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
TECH
62.3x
Bio-Techne Corporation
ISRG
43.5x
Intuitive Surgical
JNJ
31.4x
Johnson & Johnson
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
TECH
31.2x
Bio-Techne Corporation
ISRG
31.4x
Intuitive Surgical
JNJ
22.0x
Johnson & Johnson
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
TECH
1.3%
Bio-Techne Corporation
ISRG
18.5%
Intuitive Surgical
JNJ
6.6%
Johnson & Johnson
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
TECH
Bio-Techne Corporation
ISRG
26.5%
Intuitive Surgical
JNJ
-0.9%
Johnson & Johnson
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
TECH
23.5%
Bio-Techne Corporation
ISRG
33.6%
Intuitive Surgical
JNJ
29.2%
Johnson & Johnson
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
TECH
66.2%
Bio-Techne Corporation
ISRG
66.7%
Intuitive Surgical
JNJ
68.1%
Johnson & Johnson
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
TECH
15.0%
Bio-Techne Corporation
ISRG
28.4%
Intuitive Surgical
JNJ
21.5%
Johnson & Johnson
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
TECH
9.0%
Bio-Techne Corporation
ISRG
17.4%
Intuitive Surgical
JNJ
25.7%
Johnson & Johnson
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
TECH
2.0%
Bio-Techne Corporation
ISRG
1.9%
Intuitive Surgical
JNJ
2.6%
Johnson & Johnson
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
TECH
13.71x
Bio-Techne Corporation
ISRG
Intuitive Surgical
JNJ
57.71x
Johnson & Johnson
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
TECH
4.55x
Bio-Techne Corporation
ISRG
4.96x
Intuitive Surgical
JNJ
1.09x
Johnson & Johnson
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
TECH
1.28
Bio-Techne Corporation
ISRG
1.46
Intuitive Surgical
JNJ
0.23
Johnson & Johnson
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
TECH
0.4%
Bio-Techne Corporation
ISRG
Intuitive Surgical
JNJ
2.0%
Johnson & Johnson
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
TECH
-2.2%
Bio-Techne Corporation
ISRG
26.2%
Intuitive Surgical
JNJ
0.8%
Johnson & Johnson

Episode timeline

Episode archive for TECH

Each row is one earnings episode with every verified platform link available.

Q3 FY2026
Episode live
2026-05-07
Published youtube podcast complete
TECH Stock: Revenue Misses by 1% — Q3 FY2026
Quarterly earnings-analysis entry for Bio-Techne Corporation. Use the links on the right to open the video or podcast episode.